

A W Armstrong

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7211989/a-w-armstrong-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121
papers

5,114
citations

32
h-index

71
g-index

145
ext. papers

6,576
ext. citations

5.3
avg. IF

6.29
L-index

#	Paper	IF	Citations
121	Re-Classification of Psoriasis Severity: Perspectives and Controversy. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022 , 7, 7-8	1.1	
120	Economic Burden of Chronic Hand Eczema: A Review.. <i>American Journal of Clinical Dermatology</i> , 2022 , 1	7.1	1
119	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2021 , 237, 151-157	4.4	4
118	Topical opioid use in dermatologic disease: A systematic review. <i>Dermatologic Therapy</i> , 2021 , 34, e151502.2		0
117	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021 , 11, 2147-2157	4	0
116	Pemphigus and bullous pemphigoid in the United States: a 21-year analysis of patient characteristics, treatment patterns, and comorbidities. <i>Journal of Dermatological Treatment</i> , 2021 , 1-3	2.8	
115	Childhood atopic dermatitis: outpatient visit trends, demographics, and topical agents in the United States, 1995-2015. <i>International Journal of Dermatology</i> , 2021 , 60, e423-e424	1.7	
114	AB0528 COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1293-1294	2.4	
113	POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 795-1-796	2.4	8
112	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021 , 385, 130-140	39.2	28
111	Response to Letter to the Editor commenting on: "Dermatologists in social media: A study on top influencers, posts, and user engagement". <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, e165	4.5	
110	Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 455-459	2.8	4
109	Does location matter? Geographic variations in healthcare resource use for atopic dermatitis in the United States. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 314-320	2.8	3
108	Differences in wage earnings between psoriasis patients on biologics versus those on oral therapies: a population-based study in the United States. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 440-445	2.8	
107	Response to Letter to the Editor "Reply to "Dermatologists in Social Media: A Study on Top Influencers, Posts, and User Engagement": Dermatologist Influencers on TikTok". <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	1
106	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 487-498	40	51
105	Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost-effective. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35 Suppl 1, 28-34	4.6	1

104	Words matter: a randomized controlled study evaluating the impact of decision-framing on treatment preferences in adults with psoriasis and psoriatic arthritis. <i>British Journal of Dermatology</i> , 2021 , 184, 971-973	4	2
103	Differences in health care resource utilization and costs for keratinocyte carcinoma among racioethnic groups: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	1
102	Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns. <i>International Journal of Dermatology</i> , 2021 ,	1.7	
101	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2021 , 1-8	2.8	2
100	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. <i>British Journal of Dermatology</i> , 2021 ,	4	8
99	A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. <i>Journal of Medical Internet Research</i> , 2021 , 23, e29511	7.6	
98	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. <i>Dermatology</i> , 2021 , 1-8	4.4	1
97	The Use of Biologics During the COVID-19 Pandemic. <i>Dermatologic Clinics</i> , 2021 , 39, 545-553	4.2	7
96	Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2539-2541	4.3	
95	Rosacea videos on social media: A comparison of accuracy, quality, and viewer engagement. <i>Dermatology Online Journal</i> , 2021 , 27,	1	1
94	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1945-1960	27.4	268
93	Association Between the Mental Health of Patients With Psoriasis and Their Satisfaction With Physicians. <i>JAMA Dermatology</i> , 2020 , 156, 754-762	5.1	1
92	Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics. <i>Dermatology and Therapy</i> , 2020 , 10, 615-621	4	2
91	Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study. <i>Journal of Dermatological Treatment</i> , 2020 , 1-6	2.8	2
90	Dermatologists in social media: A study on top influencers, posts, and user engagement. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1452-1455	4.5	22
89	Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2020 , 1-9	2.8	3
88	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 323-338	7.1	0
87	Reply to Letter to the Editor Regarding: "Dermatologists in Social Media: A Study on Top Influencers, Posts, and User Engagement". <i>Journal of the American Academy of Dermatology</i> , 2020 ,	4.5	1

86	Defining drug-free remission of skin disease in patients with plaque psoriasis. <i>British Journal of Dermatology</i> , 2020 , 182, 1484-1487	4	1
85	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 936-945	4.5	38
84	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020 , 10, 133-150	4	29
83	Strategies to maximize clinical efficiency while maintaining patient safety during the COVID-19 pandemic: an interview-based study from private practice dermatologists. <i>Journal of Dermatological Treatment</i> , 2020 , 1-4	2.8	2
82	Report from the International Dermatology Outcome Measures Initiative. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2020 , 20, S80-S83	1.1	1
81	Who sees you matters: a population study examining topical corticosteroid prescribing patterns between primary care providers and dermatologists for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2020 , 1-4	2.8	0
80	Language proficiency and biologics access: a population study of psoriasis patients in the United States. <i>Journal of Dermatological Treatment</i> , 2020 , 1-5	2.8	1
79	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 881-890	7.1	12
78	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1704-1716	4.5	31
77	Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 452-459	2.8	2
76	Where you live matters: Regional differences in health care resource use for psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1360-1367	4.5	5
75	Engaging but inaccurate: A cross-sectional analysis of acne videos on social media from non-health care sources. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 610-612	4.5	10
74	An association between hidradenitis suppurativa and HIV. <i>British Journal of Dermatology</i> , 2020 , 182, 490-491	4	2
73	Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 617-623	2.8	1
72	Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. <i>Dermatology Online Journal</i> , 2020 , 26,	1	1
71	Effects of Online Care on Functional and Psychological Outcomes in Patients with Psoriasis: A Randomized Controlled Trial. <i>Journal of the American Academy of Dermatology</i> , 2019 ,	4.5	7
70	Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. <i>PLoS ONE</i> , 2019 , 14, e0210517	3.7	12
69	Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. <i>Archives of Dermatological Research</i> , 2019 , 311, 453-460	3.3	2

68	Exploring Mental Disorders in Patients With Skin Diseases. <i>JAMA Dermatology</i> , 2019 , 155, 660-661	5.1	
67	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1733-1741	4.6	12
66	A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 823-828	4.5	3
65	Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 135-140	2.8	7
64	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 831-839	4.0	141
63	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 2437-2446.e1	4.3	42
62	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1029-1072	4.5	296
61	Assessing Skin Biopsy Rates for Histologic Findings Indicative of Nonpathological Cutaneous Disease. <i>Dermatologic Surgery</i> , 2019 , 45, 640-649	1.7	2
60	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019 , 9, 5-18	4	44
59	Suicidality among psoriasis patients: a critical evidence synthesis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019 , 154, 56-63	0.8	3
58	Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 454-460	2.8	12
57	Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 1093-1104	5.3	35
56	Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. <i>British Journal of Dermatology</i> , 2019 , 180, 306-314	4	16
55	Association Between Atopic Dermatitis and Suicidality: A Systematic Review and Meta-analysis. <i>JAMA Dermatology</i> , 2019 , 155, 178-187	5.1	34
54	Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 27-34	2.8	10
53	An unusual spiculated presentation of follicular porokeratosis. <i>Dermatology Online Journal</i> , 2019 , 25,	1	
52	Teledermatology in the United States: An Update in a Dynamic Era. <i>Telemedicine Journal and E-Health</i> , 2018 , 24, 691-697	5.9	43
51	Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1940-1949	4.6	39

50	Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. <i>BMC Dermatology</i> , 2018 , 18, 4	2.1	14
49	Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2200-2207	4.6	22
48	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018 , 234, 157-165	4.4	7
47	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018 , 154, 1137-1144	3.4	24
46	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018 , 234, 112-119	4.4	1
45	Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. <i>Rheumatology International</i> , 2017 , 37, 97-105	3.6	36
44	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 418-431	4.5	405
43	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 701-702	4.1	5
42	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 290-298	4.5	90
41	Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data. <i>Dermatology and Therapy</i> , 2017 , 7, 97-109	4	33
40	Direct-Access Online Care for the Management of Atopic Dermatitis: A Randomized Clinical Trial Examining Patient Quality of Life. <i>Telemedicine Journal and E-Health</i> , 2017 , 23, 726-732	5.9	13
39	Psoriasis and suicidality: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 425-440.e2	4.5	59
38	Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016 , 20, 196-206	1.6	12
37	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>American Journal of Clinical Dermatology</i> , 2016 , 17, 87-97	7.1	121
36	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. <i>JAMA Dermatology</i> , 2016 , 152, 661-9	5.1	37
35	Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016 , 9, S12-S16	1.2	21
34	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016 , 43, 959-60	4.1	7
33	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , 2016 , 375, 422-34	59.2	324

32	Screening Recommendations for Chlamydia and Gonorrhea. <i>JAMA Dermatology</i> , 2015 , 151, 1014-6	5.1	0
31	Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 968-77.e2	4.5	37
30	Effect of Adhesive Strips and Dermal Sutures vs Dermal Sutures Only on Wound Closure: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2015 , 151, 862-7	5.1	17
29	Economic Burden of Psoriasis in the United States: A Systematic Review. <i>JAMA Dermatology</i> , 2015 , 151, 651-8	5.1	144
28	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015 , 373, 1318-28	59.2	530
27	Effect of Automated Online Counseling on Clinical Outcomes and Quality of Life Among Adolescents With Acne Vulgaris: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2015 , 151, 970-5	5.1	7
26	Effectiveness of a novel interactive health care education tool on clinical outcomes and quality of life in acne patients: A randomized controlled pilot study. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 435-9	2.8	5
25	Set-back versus buried vertical mattress suturing: results of a randomized blinded trial. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 674-80	4.5	25
24	Patient-centered, direct-access online care for management of atopic dermatitis: a randomized clinical trial. <i>JAMA Dermatology</i> , 2015 , 151, 154-60	5.1	36
23	Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. <i>JAMA Dermatology</i> , 2015 , 151, 432-8	5.1	49
22	The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 345-8	4.5	31
21	Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. <i>Drugs</i> , 2014 , 74, 423-41	12.1	158
20	Updates in Rosacea: Epidemiology, Risk Factors, and Management Strategies. <i>Current Dermatology Reports</i> , 2014 , 3, 23-28	1.5	6
19	Electroabrasion vs. manual dermabrasion: a randomized, double-blind, comparative effectiveness trial. <i>British Journal of Dermatology</i> , 2014 , 171, 124-9	4	6
18	Psoriasis and psoriatic arthritis educational initiatives: an update from the 2013 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1240-3	4.1	7
17	Public perception of dermatologists and comparison with other medical specialties: results from a national survey. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 875-81	4.5	17
16	Psoriasis prevalence among adults in the United States. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 512-6	4.5	518
15	Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 665-669	4.5	33

14	Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. <i>F1000Research</i> , 2014 , 3, 248	3.6	40
13	The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1227-9	4.1	16
12	Outcomes research in psoriasis and psoriatic arthritis using large databases and research networks: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1233-6	4.1	5
11	Psoriasis provoked or exacerbated by medications: identifying culprit drugs. <i>JAMA Dermatology</i> , 2014 , 150, 963	5.1	12
10	Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. <i>Archives of Dermatological Research</i> , 2013 , 305, 891-7	3.3	11
9	Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. <i>JAMA Dermatology</i> , 2013 , 149, 1180-5	5.1	238
8	Epidemiology of classic and AIDS-related Kaposi's sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005. <i>Epidemiology and Infection</i> , 2013 , 141, 200-6	4.3	19
7	The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. <i>Nutrition and Diabetes</i> , 2012 , 2, e54	4.7	281
6	A review of health outcomes in patients with psoriasis. <i>Dermatologic Clinics</i> , 2012 , 30, 61-72, viii	4.2	26
5	Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. <i>Dermatology</i> , 2012 , 225, 121-6	4.4	67
4	Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. <i>PLoS ONE</i> , 2012 , 7, e52935	3.7	177
3	Fate of manuscripts declined by the Journal of the American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 632-5	4.5	31
2	Follicular eruption on arms and legs. Phrynoderma. <i>Archives of Dermatology</i> , 2008 , 144, 1509-14		3
1	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19		2